GSK's RSV Vaccine Sales Propel Blowout Performance and Outlook Upgrade

GSK (GSK) missed Q4 earnings estimates with earnings of $0.72 per share, below the expected $0.76 per share, but surpassed revenue estimates with $10 billion for the quarter. The stock's performance will depend on management's commentary and future earnings expectations. The current Zacks Rank for GSK is #3 (Hold), indicating expected performance in line with the market. The industry outlook and performance of other companies in the same sector will also impact GSK's stock.